YES1, the most significantly upregulated gene among IO-exposed tumor cells in this cohort, may explain one specific mechanism via YAP1 (YES-associated protein), which is also associated with poor survival in treatment of treatment naïve ccRCC patients [28, 29]. This evidence concerns the gene YES1 and nonpapillary renal cell carcinoma.